<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04480840</url>
  </required_header>
  <id_info>
    <org_study_id>PLN-74809-PSC-203</org_study_id>
    <secondary_id>INTEGRIS-PSC</secondary_id>
    <nct_id>NCT04480840</nct_id>
  </id_info>
  <brief_title>Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)</brief_title>
  <official_title>A Randomized, Double-blind, Dose-ranging, Placebo-controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Primary Sclerosing Cholangitis (PSC) and Suspected Liver Fibrosis (INTEGRIS-PSC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pliant Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pliant Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2a, multicenter, randomized, double-blind, dose-ranging, placebo-controlled, study to
      evaluate the safety, tolerability, and PK of PLN-74809 in participants with primary
      sclerosing cholangitis and suspected liver fibrosis
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 10, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events and laboratory abnormalities, as assessed by CTCAE v5.0</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of PLN-74809 plasma concentrations</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Primary Sclerosing Cholangitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PLN-74809 Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PLN-74809 Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PLN-74809 Dose Level 2 following safety review of PLN-74809 Dose Level 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLN-74809 Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PLN-74809 Dose Level 3 following safety review of PLN-74809 Dose Level 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLN-74809</intervention_name>
    <description>PLN-74809</description>
    <arm_group_label>PLN-74809 Dose Level 1</arm_group_label>
    <arm_group_label>PLN-74809 Dose Level 2</arm_group_label>
    <arm_group_label>PLN-74809 Dose Level 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established clinical diagnosis of large duct PSC based on an abnormal cholangiography
             as assessed by magnetic resonance cholangiopancreatography (MRCP), endoscopic
             retrograde cholangiopancreatography (ERCP), and/or percutaneous transhepatic
             cholangiopancreatography (PTC) in the context of cholestatic liver chemistry

          -  Suspected liver fibrosis, as defined by liver stiffness measurement (LSM), assessed by
             ultrasound-based transient elastography (TE, FibroScan®)

          -  Serum ALP concentration &gt; 1.5 times the upper limit of normal (ULN)

          -  Participants receiving treatment for IBD are allowed, if on a stable dose for at least
             3 months

          -  Serum AST and ALT concentration ≤ 5 times the upper limit of normal

          -  If receiving treatment with UDCA, therapy is at a dose of &lt; 25 mg/kg/day, has been
             stable for at least 3 months before screening.

        Exclusion Criteria:

          -  Other causes of liver disease, including secondary sclerosing cholangitis or viral,
             metabolic, or alcoholic liver disease, as assessed clinically

          -  Known or suspected overlapping clinical and histologic diagnosis of autoimmune
             hepatitis

          -  Small duct PSC (evidence of PSC on historical liver histology, with normal bile ducts
             on cholangiography)

          -  Presence of liver cirrhosis as assessed by historical liver histology,
             ultrasound-based liver stiffness measurement (FibroScan® value &gt; 14.4 kPa), and/or
             signs and symptoms of hepatic decompensation (including, but not limited to, jaundice,
             ascites, variceal hemorrhage, and/or hepatic encephalopathy)

          -  Serum ALP concentration &gt; 10 times the upper limit of normal.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pliant Therapeutics Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Pliant Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pliant Therapeutics Medical Monitor</last_name>
    <phone>clintrials@pliantrx.com</phone>
    <email>clintrials@pliantrx.com</email>
  </overall_contact>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 13, 2020</study_first_submitted>
  <study_first_submitted_qc>July 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2020</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

